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Accurate diagnosis of syncope is essential because it ranges from cardiac syncope with a
very poor prognosis to neurally-mediated syncope (NMS) with a relatively favorable
prognosis. Diagnosis of syncope, however, is diﬃcult in many patients even by HUT, so a
new loading method for HUT or implanted Holter ECG monitoring will be required in the
future. The prognosis of NMS itself may be favorable, but it may cause the aggravation of
complications.
(J Arrhythmia 2006; 22: 74–85)
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I. Approach to Syncope of Unknown Etiology
Syncope is transient loss of consciousness. The
ﬁrst thing to be done after the patient regains
consciousness is to ﬁnd the cause. Making a correct
diagnosis is important because the severity of the
condition depends on the cause. Accurate diagnosis
and treatment is particularly necessary for cardiac
syncope because it is life-threatening. However, the
cause remains unknown in many patients and some
of them have a multifactorial etiology. Syncope
recurs in many patients and is often accompanied by
trauma, so some patients need treatment regardless
of the etiology. Symptoms may be aggravated if the
wrong diagnosis is made, so various problems arise
during the management of syncope.
1. Frequency of syncope
Syncope is deﬁned as sudden loss of conscious-
ness and inability to maintain an upright posture
caused by decreased cerebral blood ﬂow. Patients
with syncope account for 3 to 3.5% of all those
presenting to emergency services and it occurs in 1
to 6% of inpatients. The Framingham study followed
the occurrence of syncope over 26 years in 5,209
subjects, and the prevalence was 3.0% in men and
3.5% in women.1) A total of 822 syncope events
were assessed in the subsequent study that followed
up 7,814 subjects for an average of 17 years, and the
frequency of initial syncope was reported to be 6.2
per 1,000 subjects/year.2) Syncope is thus a symp-
tom that occurs very frequently. With respect to the
age distribution of syncope, a sudden increase occurs
in patients over 70 years old.2)
2. Classiﬁcation of syncope
Among the many methods published for the
classiﬁcation of syncope, the classiﬁcation according
to the guidelines for diagnosis and treatment of
syncope released by the European Society of
Cardiology is shown here (ESC Guidelines 2004).3)
Causes of syncope are classiﬁed into the following 5
categories: neurally-mediated (reﬂex), orthostatic
hypotension, cardiac arrhythmias as primary cause,
structural cardiac or cardiopulmonary disease, and
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cerebrovascular causes. The main limitation of this
classiﬁcation is that more than one factor is often
involved in the pathology of syncope in many
patients, and abnormal neurological reﬂexes such as
delayed or inadequate compensatory vasoconstric-
tion have a role in syncope induced by bradycardia
or tachycardia. The prognosis is poor for syncope
due to arrhythmias and structural cardiac or cardi-
opulmonary disease, which are often considered
together as cardiac or cardiogenic syncope.
3. Prognosis of syncope
Neurally-mediated syncope, such as vasovagal
syncope, has a favorable prognosis, while at the
other extreme lies cardiac syncope with a poor
prognosis. It should also be considered that the
causes diﬀer greatly between patients presenting to
an emergency unit, outpatients, and inpatients. The
common problem is that the cause remains unknown
in 13 to 47% of patients (Figure 1).4–8) According to
the report by Kapoor et al.,8) among 433 inpatients
with syncope, reﬂex syncope and orthostatic hypo-
tension accounted for 27%, which was comparable
with the proportion of 26% for cardiac syncope,
while the cause was unknown in as high as 41%. The
prognosis of cardiogenic syncope is signiﬁcantly
worse compared with that of non-cardiac syncope
and the 5-year mortality rate reaches 50%. The
mortality for syncope of unknown etiology, on the
other hand, is approximately 30% within 5 years and
there is no signiﬁcant diﬀerence with the mortality
for non-cardiac syncope of approximately 23%. It
was recently shown by the Framingham study that
the prognosis of cardiac syncope is poor whereas the
prognosis of patients with vasovagal syncope is as
good as that of persons without syncope, while the
prognosis of syncope with an unknown etiology
ranks between the other two. Such results suggest the
importance of determining the cause of syncope for
prediction of the prognosis.2)
4. Diagnosis of syncope
1) Probable cause based on medical history,
symptoms, and routine tests (Figure 2)
When a syncope patient presents for treatment, the
patient is examined, a medical history is obtained,
and routine tests are performed, such as ECG, chest
X-ray, and hematology. When a cause other than
cerebrovascular syncope is suspected, the presence
or absence of any evidence of cardiac disease on
routine tests becomes a signiﬁcant point for making
a diﬀerential diagnosis. Whether the history of
syncope is long or short is another important point
for diﬀerentiation. Cardiac syncope should be
suspected in patients with a course of 4 years or
less versus neurally-mediated syncope (NMS) in
patients with a longer course.9)
The posture and symptoms at the onset of syncope
are also important for predicting the diagnosis.
Author VVS Other Reflex Orthostatic Cardiac Metabolic Neurogenic Psychogenic Unkown
Eagle 64(36) 3(2) 11(6) 15(9) 7(4) 5(3) 2(1) 69(39)
Day 57(29) 2(1) 7(4) 17(9) 13(7) 5(4) 14(7) 25(13)
Martin 63(37) 4(2) 13(8) 7(4) 3(2) 15(9) 1(1) 64(38)
Silverstein 1(1) 1(1) 4(4) 42(39) 4(4) 5(5) 51(47)
Kapoor 35(8) 37(9) 43(10) 110(26) 9(2) 17(4) 3(1) 179(41)
ER (Eagle,Martin)
VVS
Reflex
Orthostatic
Cardiac
Metabolic
Neurogenic
Psychogenic
ICU (Silverstein)
Figure 1 Cause of syncope.5–7)
The common problem is that the cause remains unknown in 13 to 47% of patients.
VVS: vasovagal syncope; Reﬂex: Other reﬂex syncope; Orthostatic: Orthostatic hypotension; Cardiac:
Cardiac syncope; Metabolic: Syncopy due to metabolic disturbance; Neurogenic: Syncope due to
neurological disease; Psychogenic: Syncope due to psychological disease; Unknown: Syncope of unknown
origi.
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(1) Posture at the onset of syncope
NMS only develops in the standing or sitting
position. Many people experience NMS while stand-
ing in a commuter train during the morning rush
hour. NMS may also develop during dental treat-
ment, even in the sitting position. Cardiac syncope
can occur regardless of the posture.
(2) Causes of syncope
The situations that generally induces NMS include
uncomfortable scenes, sounds, odors, pain, standing
up for a long time, sudden standing after lying prone
or sitting for a long time, hypoxemia, fever, hunger,
dehydration, heavy intake of alcohol, and blood loss.
Situational syncope develops at the time of mictur-
ition, defecation, swallowing, coughing, or after
exercise. Cardiac syncope induced by ventricular
tachycardia or ventricular ﬁbrillation may develop
due to a change in autonomic tone such as when
awakening or during/after exercise. Idioventricular
ﬁbrillation may also develop during sleep, but it
often causes sudden death rather than syncope.
Syncope due to vasospastic angina is followed by
chest pain and occurs at a time of high stress, while
smoking, after exercise, or on getting up in the
morning.
(3) Time of onset
Syncope frequently occurs at a certain time of day
depending on its cause. As described above, idio-
ventricular ﬁbrillation due to vasospastic angina or
Brugada syndrome occurs spontaneously during the
nighttime or early morning. Torsade des pointes in
patients with congenital long QT syndrome develops
on awakening, during the daytime, or while exercis-
ing. NMS may occur at any time, but syncope
associated with micturition or defecation is likely to
happen at night. Vasovagal syncope tends to occur in
the morning.
(4) Prodromal symptoms and symptoms at the
time of syncope
A sensation of hotness, thirst, or feeling of
suﬀocation are the initial prodromal symptoms of
NMS, while gastric discomfort, belching, abdominal
pain, a desire to defecate, sighing, yawning, blurred
vision, palpitations, or dizziness may develop at the
same time or immediately afterward. The patient
then becomes pale with dilated pupils and sweating,
after which he/she loses consciousness. When the
prodromal symptoms last for 10 seconds or more,
NMS can be strongly suspected.9) Rigidity of the
limbs, tremor, and convulsions may also occur at the
time of syncope. The patient complains of nausea,
tremor, and headache even after recovery and often
has a desire to urinate. Cardiac syncope may be
accompanied by prodromal symptoms such as
palpitations or chest pain, but these do not last for
very long and syncope occurs rapidly. Among the
types of NMS, few prodromal symptoms are asso-
ciated with cardioinhibitory syncope or situational
syncope. Elderly patients may have few prodromal
symptoms.
Syncope
Heart disease
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Heart disease
(−)
History
<=4 yrs
History
>4 yrs
While supine
Exercise
Blurred vision
Convulsion
Cardiac
Abdominal
discomfort
Nausea
Pallor
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Palpitation
(+)
Prodominal
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Figure 2 Probable based on medical history, symptoms, and routine tests.
When a cause other than cerebrovascular syncope is suspected, the presence or absence of any evidence of
cardiac disease on routine tests becomes a signiﬁcant point for making a diﬀerential diagnosis. Whether
the history of syncope is long or short is another important point for diﬀerentiation. Cardiac syncope
should be suspected in patients with a course of 4 years or less versus neurally-mediated syncope (NMS) in
patients with a longer course. The posture and the symptoms at the onset of syncope are also important for
predicting the diagnosis.
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2) Investigation of syncope (Figure 3)
Whether syncope has a cerebrovascular or cardi-
ovascular cause is judged from the symptoms
observed and the results of routine tests. Cerebral
computer tomography (CT) scanning and magnetic
resonance imaging are often performed as an initial
test because it is widely available in Japan, but
the incidence of cardiovascular syncope is high so
Holter ECG monitoring, the head-up tilt test (HUT),
carotid sinus massage (CSM), and echocardiography
should actually be performed ﬁrst to identify cardio-
vascular causes, except when a cerebrovascular
etiology is strongly suspected. If the patient has
arrhythmia, exercise testing, ventricular signal-aver-
aged electrocardiogram, and T-wave alternans are
performed, and cardiac electrophysiological study of
the heart may also be required. When ischemic heart
disease is suspected, exercise scintigraphy and
cardiac angiography should be performed. If cere-
brovascular syncope is suspected, on the other hand,
brain CT scanning, brain MRI, cervical Doppler
ultrasound and electroencephalography should be
performed. Neuropsychiatric evaluation should be
done if all of the above tests are negative. The most
important test for elucidating the cause of syncope is
head-up tilt test.
(1) Head-up tilt test (HUT)
This test is useful for diagnosis of neurally
mediated syncope (NMS), which accounts for ap-
proximately 30% of all syncope. When we employed
the method of making the patient stand for 30
minutes at a slope angle of 80, prodromal symptoms
or syncope were induced in 68 subjects (27%)
among 249 consecutive patients with syncope of
unknown etiology.10) The positive rate was a high
53% in young patients under 25 years old, whereas it
was only 13% in patients over 50 years old. Among
drug provocations employed to reduce the false-
negative rate, isoproterenol is the most commonly
used. Among 153 of 249 patients who were negative
in the control tilt test, 78 patients (51%) became
positive with isoproterenol. When the results of the
control tilt test and isoproterenol loading test were
combined, 148 out of 249 patients (59%) were
diagnosed as NMS, but the cause was unknown in
41%. The proportion of patients with an unknown
etiology was higher among the elderly. It seems that
the HUT has a high detection rate for vasovagal
syncope that is common in young patients, whereas
its detection rate is low for reﬂex syncope such as
micturition syncope that is common in the elderly.
Also, there are often multiple factors causing
syncope in the elderly, such as administration of
antihypertensive therapy, vasodilators, etc. or cere-
bral arterial stenosis. It is also possible that cardiac
syncope with a poor prognosis may be masked in the
History, physical exam, ECG
`
 chest XP
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 Blood
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Cerebral MRI
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Carotid Doppler
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Cardiovascular
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Figure 3 Investigation of syncope.
Whether syncope has a cerebrovascular or
cardiovascular cause is judged from the symp-
toms observed and the results of routine tests.
Cerebral CT scanning is often performed as an
initial test because it is widely available in
Japan, but the incidence of cardiovascular
syncope is high so Holter ECG monitoring, the
head-up tilt test (HUT), carotid sinus massage
(CSM), and echocardiography should actually
be performed ﬁrst to identify cardiovascular
causes, except when a cerebrovascular etiology
is strongly suspected. If the patient has arrhyth-
mia, exercise testing, ventricular signal-aver-
aged electrocardiogram, and T-wave alternans
are performed, and cardiac electrophysiologic
study may also be required. When ischemic
heart disease is suspected, exercise scintigraphy
and cardiac angiography should be performed. If
cerebrovascular syncope is suspected, on the
other hand, brain CT scanning, cervical Doppler
ultrasound, cervical MRI, and electroencepha-
lography should be performed. Neuropsychiatric
evaluation should be done if all of the above
tests are negative.
CT: computed tomograpy; MRI: magnetic res-
onance imaging; Carotid Doppler: carotid dop-
pler ultrasonography; CSM: carotic sinus mas-
sage
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elderly. The cause should therefore be identiﬁed as
clearly as possible, and loading tests with nitrates or
ATP have also been employed in recent years
(Figures 4, 5). In order to assess the eﬀectiveness of
the treatment using HUT, a high reproducibility is
needed. The acute reproducibility is higher than the
chronic reproducibility.11–16) Although the use of
HUT for assessing the eﬀectiveness of diﬀerent
treatments has important limitations,17,18) the assess-
ment of drug treatment using HUT in the acute phase
may be useful for predicting follow-up results.19)
(2) Implantable loop recorder
It was recently reported that the implantable loop
recorder (ILR) is useful for the diagnosis of syncope
and that its diagnostic rate is signiﬁcantly higher
compared with ordinary methods.
The ILR is as small as a ﬁnger and has no lead,
and observation is possible for 14 months. At the
onset of an event, the ECG can be recorded for up to
40 minutes before the event when the patient pushes
the activating switch. Several types of recording are
possible depending on the pattern of syncope and
automated recording is also possible.
Among several of the ILR, the results of the
Randomized Assessment of Syncope Trial (RAST)
are shown below.20) The subjects were 60 syncope
patients with an unknown etiology who showed no
abnormalities on HUT, Holter ECG for at least 24
hours, and echocardiography. An external loop
recorder (wearable for about 1 week), HUT, and
electrophysiological testing were used for 30 sub-
jects in the conventional test (CV) group, whereas 30
other subjects were randomly allocated to the ILR
group and were observed for 12 months. The groups
were crossed over when a diagnosis could not be
made. The ILR diagnostic rate was signiﬁcantly
higher (52%) compared with that of ordinary
methods (20%). The diagnostic rate achieved with
ILR was even higher (62%) after crossover when a
diagnosis could not be made by ordinary methods.
When the results obtained before and after crossover
were combined, ILR diagnosis was possible in 55%
of the patients, which was signiﬁcantly higher than
19% for the standard methods. Arrhythmia was the
most frequent diagnosis made by ILR, with 14
patients having bradycardia and 3 patients having
tachycardia.
5. Problems with syncope
1) Recurrence
The percentage of patients with recurrent syncope
is very high (37 to 47%) and some patients
frequently attend the emergency unit.4,5,8)
2) Trauma
One of the problems associated with syncope is a
high incidence of trauma, since the rate of occur-
rence at the time of syncope ranges between 16 to
35%.5,8) The trauma rate among NMS patients was
13% according to our statistics. When we tried to
determine the type of patient most likely to suﬀer
from trauma, we found that NMS induced by HUT
was of the cardioinhibitory type and trauma was
observed in 78% of patients with cardiac arrest
lasting for 4 seconds. This was signiﬁcantly higher
compared with the rate of 20% for patients with
cardiac arrest lasting <4 seconds. Attention should
be paid to cardioinhibitory syncope because it
develops without prodromal symptoms, and HUT
should be performed for prediction of trauma.
3) Driving and syncope patients
a. Cardiac syncope
The high recurrence rate of syncope places various
limitations on daily life,21,22) and interference with
driving is observed in 60% of patients. Patients with
potentially fatal ventricular arrhythmias continued to
drive in a comparative study of antiarrhythmic drug
therapy and implantable cardiovertor deﬁbrillator
(ICD) (Antiarrhythmic Versus Implantable Deﬁbril-
lator: AVID).23) In the AVID study, the eﬀect of
antiarrhythmic drugs and the implantable deﬁbrilla-
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Figure 4 NMS induction rate by head-up tilt test without
drug provocation.10)
When we employed the method of making the patient stand for 30
minutes at a slope angle of 80, pre-syncope or syncope were
induced in 68 subjects (27%) among 249 consecutive patients with
syncope of unknown etiology. The positive rate was a high 53% in
young patients under 25 years old, whereas it was only 13% in
patients over 50 years old.
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tor was compared in patients resuscitated from life-
threatening ventricular arrhythmia. An anonymous
questionnaire was mailed to each patient participat-
ing in the study to obtain information about driving
habits and experiences. It was found that 88% of the
patients resumed driving within 12 months and 2%
of them had experienced syncope during driving.
During driving, electrical shocks were delivered by
ICD in 8% of the 295 patients with a deﬁbrillator.
Fifty patients reported at least 1 accident and a total
of 55 accidents were reported during the follow-up
period after resuming driving (3.4% per patient-
year). It was concluded that development of symp-
toms related to arrhythmia occurred frequently
during driving, but accidents were uncommon, with
the frequency being lower than 7.1%, which was the
annual accidents rate of the general driving popula-
tion in the USA. This frequency, however, would be
higher here than in the USA when considering the
traﬃc situation in Japan.
b. Syncope during driving in NMS patients
Li et al.24) reported on syncope during driving
in 245 successive patients undergoing HUT. Of the
23 patients (9%) who had syncope during driving, 19
were HUT positive and 4 were negative. Nine
patients had accidents and 1 of them caused the
death of another driver. Seven of the patients who
had accidents were HUT positive. Although 4
patients were HUT negative, they still had syncope
during driving and 2 of them caused accidents. This
means that a negative HUT dose not necessarily
guarantee safety during driving. Bhatia25) reported
that 2 of 155 patients with HUT-induced NMS
suﬀered from syncope during driving and 1 of them
was injured. In our study, 2 out of 175 patients with
HUT-induced NMS had syncope during driving and
1 of them was injured. The above results show that
car accidents are not uncommon in NMS patients
and driving should be prohibited for patients who are
HUT-positive and have the cardioinhibitory type of
syncope. NMS may improve in some patients over
time, so the possibility of driving again should be
investigated periodically.
II. Treatment of Syncope
1. Treatment of cardiac syncope
Most patients regain consciousness shortly after
an attack of syncope, but cardiac syncope should be
treated according to the underlying disease. Many
NMS patients also have arrhythmias, as described
below, and HUT should be performed in suspected
cases.
2. Treatment of NMS
Prevention is the major therapeutic measure for
NMS and few patients require emergency treatment.
Which patients require treatment for NMS and
whether HUT is useful for conﬁrming the eﬃcacy
of therapy remains a big issue. Grimm et al.26) inves-
tigated this problem in 80 untreated patients with
suspected NMS who experienced at least 1 episode
of syncope, had no cardiac disease, and had no other
obvious cause of syncope. Thirty-nine of these
patients formed a group with only one syncope
attack (group A) and 41 formed a group with 2
or more attacks (group B). NMS developed in 4
patients (10%) from group A and 10 patients (24%)
from group B (p ¼ 0:1). A signiﬁcant diﬀerence was
observed in the recurrence of syncope over 23 8
months since the rate was 10% in group A and 54%
in group B (p < 0:5), but no diﬀerence in recurrence
was observed regardless of a positive or negative
baseline tilt test (43% vs. 30%). In other words,
recurrence was not observed in 90% of the untreated
patients with 1 syncope attack regardless of their
HUT results, but patients with 2 or more attacks
should be treated. Given that there was no diﬀerence
of the HUT-positive rate between patients with
recurrence and non-recurrence, it was concluded that
HUT was not eﬀective for predicting the recurrence
of syncope in untreated patients. Among the patients
in our study, recurrence was not observed in 20 out
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Figure 5 NMS induction rate by head-up tilt test in addition
to isoproterenol provocation.10)
Among drug provocations employed to reduce the false-negative
rate, isoproterenol is the most commonly used. Among 153 of 249
patients who were negative in the control tilt test, 78 patients
(51%) became positive with isoproterenol. When the results of the
control tilt test and isoproterenol loading test were combined, 148
out of 249 patients (59%) were diagnosed as NMS, but the cause
was unknown in 41%.
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of 21 patients (94%) for whom propranolol was
eﬀective and 12 out of 13 patients (92%) for whom
disopyramide was eﬀective according to the HUT.
Syncope recurred in all of 15 patients in whom an
eﬀective drug could not be found by HUT.19) It is
therefore considered that treatment with a drug
shown to be eﬀective by HUT is useful for
prevention of recurrence. The value of HUT is thus
controversial for prediction of recurrence in un-
treated patients and for judgment of treatment
eﬃcacy.
There is no consensus with respect to the period
for which treatment should be continued, but we
discontinue drug therapy after dose reduction when 1
year has passed without symptoms because remis-
sion is observed over the long-term and recurrence
often occurs within 1 year after the initial attack.
However, discontinuation of treatment should be
carefully decided in patients who frequently develop
syncope or who suﬀer from trauma, and the drug
doses should be adjusted by repeating HUT. Many
drugs have been used in the treatment of NMS (beta-
blockers, disopyramide, scopolamine, clonidine, the-
ophilline, ﬂudrocortisone, ephedrine, etilefrine,
midodrine, clonidine, serotonin reuptake inhibitors,
etc.). In general, while the results have been
satisfactory in uncontrolled trials or short-term
controlled trials, several long-term placebo-control-
led prospective trials have been unable to show a
beneﬁt of the active drug over placebo.17,18,27–33) with
one exception.34) This revealed that subjects may not
be homogeneous because NMS results from multi-
factral causes such as eﬀectors and the central nerve
system. So, the eﬀective therapy will not be homo-
geneous, but it depends on the individual patient.
Recently, in the patients with recurrent NMS, the
prescription of progressively prolonged periods of
enforced upright posture (so-called ‘tilt-training’)
may reduce syncope recurrence.35–38)
3. Arrhythmia and syncope
Adams-Stokes syndrome and NMS can be diﬀer-
entiated by reference to the posture and symptoms at
the onset of syncope. However, even if an arrhyth-
mia that is likely to induce syncope is detected by
Holter ECG or EPS, syncope should not be instantly
diagnosed as Adams-Stokes syndrome because vaso-
vagal reﬂexes may contribute to syncope in some
arrhythmia patients. For instance, Brignole et al.39)
reported that bradyarrhythmic syncope induced by
carotid sinus massage and HUT in 60% and 54%,
respectively, of the patients were diagnosed as sick
sinus syndrome (SSS). It was also reported that 80%
of them showed a positive HUT at least once, 69% of
them showed a cardioinhibitory response or mixed
response, and 11% of them showed a vascular
inhibitory response, indicating that autonomic re-
ﬂexes were involved in syncope among SSS patients.
Among these patients, syncope is likely to recur in
those who still show a vascular inhibitory response
or mixed response after implantation of a pace-
maker.40) We have also experienced bradyarrhythmic
patients with recurrence of syncope after implanta-
tion of a pacemaker, and reported a subject in whom
syncope was induced by HUT.41) Some of these
patients already had suspected NMS at the time of
pacemaker implantation, or NMS developed after
implantation. In any case, implantation of a pace-
maker is the ﬁnal treatment method for syncope due
to bradycardia and HUT should be performed in
patients for whom this indication is even slightly
applicable. Involvement of neural reﬂexes has also
been reported with regard to the relationship be-
tween bradyarrhythmia and syncope. When HUT
NMS (+)
NMS (−)
26%
74%
59%32%9%
Cardioinhibitory type
Vasodepressor type
Mixed type
Arrhythmias-group
Figure 6 NMS in the patients with arrhythmias.43)
We performed HUT in 55 patients who developed syncope of
unknown etiology with some type of arrhythmia. NMS was
detected in 41 patients (74%) by control HUT or isoproterenol
loading.
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was performed during sinus rhythm and tachycardia
to investigate the involvement of vasovagal reﬂexes
in syncope associated with supraventricular tachy-
cardia (SVT), syncope developed with HUT during
tachycardia in 7 out of 22 patients.42) The blood
pressure decreased signiﬁcantly in patients who
developed syncope, but a signiﬁcant diﬀerence of
the heart rate was not observed compared with the
patients who did not develop syncope. Because 6 out
of 7 patients developed syncope with HUT during
sinus rhythm, it was concluded that vasomotor
factors rather than a rapid heat rate per se were
involved in syncope during tachycardia. We also
performed HUT in 55 patients who developed
syncope of unknown etiology with prodromal symp-
toms and some type of arrhythmia. NMS was
detected in 41 patients (74%) by control HUT or
isoproterenol loading43) (Figure 6). In addition, NMS
was induced in 76% of patients with tachyarrhyth-
mias including extrasystole, and aggravation of
arrhythmia was observed immediately before syn-
cope in half of them (Figures 7A and 7B). Further-
more, NMS was induced in 73% of patients with
bradyarrhythmia, and half of them had the cardioin-
hibitory type or mixed type in whom bradycardia
was further aggravated (Figure 8).
Arrhythmia and NMS often develop at the same
time and are closely related, so the cause of syncope
should be carefully determined to select the best
treatment.
4. Is the prognosis of NMS really good?
Kikushima et al. reported that epinephrine is
excessively secreted just before NMS11) (Figure 9).
Furthermore, when heart rate variability is measured
upon induction of NMS, the high-frequency (HF)
component (which indicates vagal tone) decreases
after standing up while the LF/HF ratio (indicating
sympathetic tone) vises and HF increases immedi-
ately before the onset of syncope44,45) (Figure 10).
This ‘‘autonomic turmoil’’ aggravates the underlying
disease and may sometimes induce a serious out-
come, so it should be carefully identiﬁed.
A. Tachyarrhythmias-group
B
NMS (+)
NMS (−)
24%
76%
54% 46%
25% 68%7%
Cardioinhibitory type
Vasodepressor type
Mixed type
No change in
Arrhythmias
Increase in
Arrhythmias
An increase in extrasystole immedi-
ately before syncope. In 46% of tachy-
before the development of syncope.
arrhythmia patients, neurally mediated
syncope was accompanied by an
increase in extrasystoles immediate
Figure 7 NMS in the patients with tachyarrhythmias.43)
In addition, NMS was induced in 76% of patients with tachyarrhythmias including extrasystole, and aggravation of
arrhythmia was observed immediately before syncope in half of them.
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Diseases inﬂuenced by vagal tone
(1) Vasospastic angina46,47)
We have treated a patient in whom vasospastic
angina was induced at the onset of NMS.47)
(2) Brugada syndrome
The association of NMS and this syndrome has
been reported.
(3) Atrial ﬁbrillation
Atrial ﬁbrillation is sometimes induced at the
onset of NMS.
Diseases inﬂuenced by sympathetic tone
(1) Long QT syndrome48–50)
We have treated a patient with NMS and long QT
syndrome in whom the QT interval was extremely
variable.
(2) Ventricular arrhythmia
According to the report of Shinohara43) mentioned
above, aggravation of arrhythmia was observed
immediately before syncope in half of their tachyar-
rhythmia patients who had NMS.
5. Syncope in hypertensive patients
Soteriades, E. S.2) reported that syncope was
induced by drug therapy in 10% of their patients.
Among the drugs causing syncope, antihypertensive
agent and coronary vasodilators (nitrates) induce
orthostatic hypotension and NMS, whereas -ago-
nists and cilostazol only induce NMS. Drugs that
cause prolongation of the QT interval induce
syncope due to torsade de pointes. For performing
antihypertensive therapy which avoids induction of
NMS, neither activation of sympathetic tone nor
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Figure 9 Epinephrine is excessively secreted just before NMS.11)
Propranolol could not inhibit excessive epinephrine in the patients who developed syncope during HUT without isoproterenol provocation
(isoproterenol independent group: upper panel) though it was suppressed to a low level of epinephrine in the patients who developed
syncope with isoproterenol provocation (isoproterenol-dependent group).
Bradyarrhythmias-group
NMS (+)
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27%
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46% 39%15%
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Figure 8 NMS in the patients with bradyarrhythmias.43)
NMS was induced in 73% of patients with bradyarrhythmia, and
half of them had the cardioinhibitory type or mixed type in whom
bradycardia was further aggravated.
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maintenance of normal baroreceptor sensitivity are
required. Thus, -blockers are used for treatment of
NMS and are also useful for treatment of hyper-
tension complicated by NMS. It was recently
reported that angiotension II receptor antagonists
also maintain normal baroreceptor sensitivity.51,52)
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